Skeletal Disorder TRIZ Cases

Systemic NRTI treatment addresses osteoarthritis by reducing inflammation and cartilage degeneration while avoiding joint replacement surgery.

Platelet-rich plasma and FGF-pretreated fibroblasts boost disc matrix synthesis and curb degeneration in spinal disc repair.

Flexible humanized anti-CD40 antibody dosing helps treat rheumatoid arthritis when JAKi or DMARD response is inadequate or intolerable.

Yeast shells enable oral macrophage targeting via Dectin-1 while improving GI stability and reducing inflammatory side effects in RA.

Low-dose subcutaneous anti-CD38 antibodies maintain efficacy while reducing red-blood-cell-related side effects and infusion burden.

Alcohol-extracted Liriodendron chinense lowers serum uric acid and helps relieve renal dilation, glomerulosclerosis, and fibrosis.

Scaffold-free 3D tissue from synovium-derived mesenchymal stem cells improves disc graft engraftment and supports longer-lasting regeneration.

CCL5 with GROβ and AMD3100 mobilizes hematopoietic stem cells into peripheral blood and improves engraftment after transplantation.

Fermented Morinda citrifolia extract uses Lactobacillus plantarum fermentation to inhibit inflammatory and cartilage-degrading factors in osteoarthritis.

A high-affinity anti-vaspin nanobody blocks cartilage degradation in osteoarthritis by targeting cryptic epitopes inaccessible to conventional antibodies.

Anti-CD45 antibodies and ADCs selectively deplete CD45+ cells to enable lower-toxicity autoHSCT conditioning and broader autoimmune patient eligibility.

A triblock-diblock biodegradable copolymer depot morselizes in joints to extend synovial drug retention and tune release over time.

Cultured allogeneic chondrocytes on a resorbable collagen membrane repair chondral defects in one procedure and help prevent further cartilage degradation.

Localized alendronate delivery in a hydrogel-silica bone filler improves retention and release control while reducing systemic side effects.

Mechanical morselization of a triblock-diblock biodegradable joint depot improves synovial retention and modulates drug release.

SPRF from platelet-rich fibrin boosts chondrocyte proliferation while limiting redifferentiation and improving consistency over PRP.

Covalently crosslinked non-alginate hydrogel microparticles improve cell encapsulation biocompatibility while enabling tunable degradation and sustained release.

A biocompatible SIS matrix helps muscle-derived progenitor cells survive, integrate, and augment bone while limiting migration and inflammation.

rAAV delivery of miR-214-3p inhibitors and miR-34a-5p boosts osteogenesis while limiting osteoclastogenesis in osteoporosis.

Long-chain butyrate triglycerides mask unpleasant odor and taste while resisting gastric lipolysis to deliver butyrate for bone health.

Quarterly denosumab targets RANKL-driven bone erosion in erosive hand OA, slowing joint damage and supporting remodeling.

Amatoxin linked to CD37-targeting antibodies delivers potent cytotoxicity to resistant B-cell malignancies, including lymphoma and CLL.

RAFT-polymerized dexamethasone conjugates enable targeted, controlled release at inflammatory sites to extend arthritis treatment effects.

A quinoline derivative treats rheumatoid arthritis while reducing side effects and offering a lower-cost alternative to biologic DMARDs.

Higher oral piclidenoson dosing at 300-2000 µg/kg improves osteoarthritis symptoms in non-human mammals while maintaining tolerability.

A 3D scaffold combining platelet lysate and adipose-derived cells recreates adipocyte growth and hematopoietic cell trapping for longer-term study.

Cultured allogeneic chondrocytes seeded on a resorbable collagen membrane support single-step cartilage repair and help prevent progressive degradation.

Isolated vaPS cells provide a broadly available pluripotent source that follows tissue microenvironment cues without genetic modification.

Sterilized multipotent cell or microvascular tissue compositions enable ready-to-use allogeneic repair while lowering rejection and viral transmission risk.

Magnetic sorting enriches N-cadherin positive MSCs from Wharton's jelly for joint injection to repair cartilage and suppress inflammation.

Injectable microgels shield iPSC-derived notochordal cells in degenerated discs, improving survival, host integration, and pain relief.

Ex vivo expansion of autologous MDSCs with SHIP-1 inhibitors offers rheumatoid arthritis control while lowering infection and malignancy risk.

Microparticles loaded with differentiation factors improve nutrient delivery in cell spheroids, boosting EV yield and cartilage regeneration.

Injected fibroblasts use disc mechanical stress to become chondrocyte-like cells, helping restore disc height, function, and pain relief.

Micronized eggshell particles reinforce crosslinked hydrogels to improve scaffold strength, porosity, degradability, and osteogenic bone repair.

MCIM compounds modulate mitochondrial activity to control inflammation while promoting tissue repair and reversing arthritis damage.

A PIK3CA inhibitor is applied to PROS and CLOVES cases to curb tissue overgrowth, improve organ dysfunction, and shrink vascular tumors.

Early-passage TGF-β1 measurements identify stem cells with enhanced cartilage differentiation for arthritis cell therapy.

These antibodies target a defined GM-CSFRα epitope to improve binding affinity and block GM-CSF receptor activity.

Zfp217 inhibition steers bone marrow stem cells toward osteoblasts, helping address bone loss and marrow-fat accumulation in osteoporosis.

Combining dexamethasone with decanoic acid targets osteoarthritis inflammation while lowering corticosteroid exposure linked to cartilage loss and bone fractures.

An iPSC-derived mitochondrial composition uses UCP2-linked activity to suppress cartilage degradation and support regeneration in osteoarthritis.

BYL719 targets the PIK3CA pathway to address vascular malformations and tissue overgrowth in CLOVES syndrome while balancing side effects.

Bisphosphonate side effects are addressed by opening osteocyte Cx43 hemichannels to release factors that inhibit tumor migration.

Combining α-KG and NMN promotes osteogenic differentiation while limiting marrow adiposity, addressing bone loss and body-weight changes.

Unfavorable physicochemical properties limit β-catenin/TCF inhibitors; bridged cyclic peptides improve uptake and Wnt pathway blockade.

Selective anti-CD45 antibody or ADC depletion targets autoreactive immune cells, reducing conditioning toxicity and broadening eligibility for autoHSCT.

Neutralizing ALK2 antibodies target activin signaling to address bone disease and anemia while potentially limiting unwanted treatment effects.

Kynurenic acid analogs inhibit hepatic XOD to reduce uric acid, creatinine, and blood urea nitrogen in hyperuricemia.

Cup-shaped organoids improve central oxygen and nutrient delivery during self-assembly.

This case uses early apoptotic cells or supernatant near affected joints to modulate immunity and slow cartilage and bone degeneration.